Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity.
Hamid Riazi-EsfahaniAlireza MahmoudiMehdi SanatkarAfsar Dastjani FarahaniFatemeh BazvandPublished in: International journal of retina and vitreous (2021)
While the regression rate in the IVA group was significantly higher than in the IVB group, the recurrence rate was significantly more in the IVA group, which may be attributed to differences in the pharmacokinetics of these drugs in the vitreous body.